References of "Herion, Francine"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailDramatic osteonecrosis of the jaw associated with oral bisphosphonates, periodontitis and dental implant removal
Ayora, A F; HERION, Francine ULg; ROMPEN, Eric ULg et al

in Journal of Clinical Periodontology (in press)

Osteoporosis affects millions of elderly patients, and anti-resorptive drugs (ARD) such as bisphosphonates (BP) represent the first-line therapy. Despite the benefits related to the use of these ... [more ▼]

Osteoporosis affects millions of elderly patients, and anti-resorptive drugs (ARD) such as bisphosphonates (BP) represent the first-line therapy. Despite the benefits related to the use of these medications, osteonecrosis of the jaw is a significant complication in a subset of patients receiving these drugs. CASE PRESENTATION: This report documents a case of dramatic bisphosphonate-related osteonecrosis associated with periodontitis and dental implant removal in an osteoporotic patient treated with per os bisphosphonates for an uninterrupted period of 15 years. CONCLUSION: The aim of this report was to discuss the administration period of BP in the treatment of osteoporosis, the decision-making and clinical management of severe MRONJ and the indications for dental implant placement in these specific patients. [less ▲]

Detailed reference viewed: 14 (8 ULg)
Peer Reviewed
See detailDRAMATIC OSTEONECROSIS OF THE JAW ASSOCIATED WITH ORAL BIPHOSPHONATES TREATMENT AFTER IMPLANT REMOVAL: A CASE REPORT
FERNANDEZ AYORA, Alberto ULg; HERION, Francine ULg; LAMBERT, France ULg et al

Poster (2013, October)

BACKGROUND Osteoporosis affects millions of elderly patients. Bisphosphonates represent first-line therapy. Osteonecrosis of the jaws in patients treated with bisphosphonates is mostly associated with ... [more ▼]

BACKGROUND Osteoporosis affects millions of elderly patients. Bisphosphonates represent first-line therapy. Osteonecrosis of the jaws in patients treated with bisphosphonates is mostly associated with intravenous bisphosphonates while the incidence associated with oral bisphosphonates is not significant. AIM This report documents a case of bisphosphonate-related osteonecrosis of the jaw (BRONJ) after dental implant removal in an osteoporotic patient treated with alendronate and risedronate for 15 years. MATERIAL AND METHODS An 83-years-old patient with no significant systemic disease underwent implant removal in the first molar left hemimandible position in 2010 due to a peri-implantitis. The surgical procedure was uneventful thought preventive measures were no taken. In June 2011, the patient was referred to our department with a wide bone sequestration of the left mandibular body. A panoramic radiograph showed an increased bone marrow density with bone sequestration. Since then, the patient underwent several courses of antibiotics and conservative therapy, without relief of symptoms. RESULTS Since 2011, the patient has lost 13 teeth in the mandible and the osteonecrosis has disseminated to the entire jaw and the left mandible condyle. The patient has even lost the left hearing. Resective surgery under general anesthesia is not indicated due to the risk because of the age of the patient. CONCLUSION AND CLINICAL IMPLICATIONS Despite the low risk of BRONJ occurrence after implant surgery in oral N-BP users, the fate of dental implants in these patients remains uncertain. Therefore patients at risk must be given a full explanation of the potential risks of implant failure and BRONJ development. Osteonecrosis of the jaws in association with bisphosphonate therapy is a very serious condition with which all dentists should be familiar. Since the treatment of BRONJ is difficult, prevention is the main goal. When the osteonecrosis begins, it can be very painful to the patient, difficult to treat, and can lead to very deleterious sequelae. [less ▲]

Detailed reference viewed: 78 (8 ULg)
Peer Reviewed
See detailDental extractions in patients treated with intravenous bisphosphonates and risk of osteonecrosis of jaws.
GAUDIN, Elise ULg; HERION, Francine ULg; ROMPEN, Eric ULg et al

Poster (2012, June)

Aim : Dental extraction remains contra-indicated in patients treated with intravenous (IV) bisphosphonates for oncology reasons because of the high risk of bisphosphonate-related osteonecrosis of the jaw ... [more ▼]

Aim : Dental extraction remains contra-indicated in patients treated with intravenous (IV) bisphosphonates for oncology reasons because of the high risk of bisphosphonate-related osteonecrosis of the jaw (BRONJ). The objective of the present abstract was to present a preventive tooth extraction protocol in patients treated with IV bisphosphonates based on the surgical removal of the alveolar process. The second objective was to identify potential risk factors to develop BRONJ. Material and Methods : 17 patients treated with IV bisphosphonate and needing at least a tooth extraction, were included. A standardized extraction protocol was followed, including alveolectomy of at least 50% of the alveolar process, pre and post-operative antibiotherapy was administrated. The patients were followed for a mean period of 29 months (min:3 -max:62). Results : In all, 17 patients and 22 extraction sites mandible (15), maxilla (7) were involved in the study. No signs of inflamed tissue or necrotic exposed bone in any patient were observed during the follow-up period and the level of comfort for the patient was improved in all cases. Nevertheless, when a careful screening of the healing area was made using a probe, in 4 out of 22 (18,2%) sites, a remaining bone contact was found and appeared to be related location (mandible), duration of biphosphonate treatment and to concomitant. Conclusion : The present cases series suggests that the described extraction protocol in IV biphosphonate patients allowed 100% bone healing and complete soft tissues healing in 81.8% of the extraction sites.The sites that have not fully recovered seemed to be related to different factors. [less ▲]

Detailed reference viewed: 26 (2 ULg)
Full Text
Peer Reviewed
See detailEffect of Ketoprofen on Paf-Induced Bovine Platelet Aggregation
Bastos da Silva, Miriam; Gustin, Pascal ULg; Herion, Francine ULg et al

in Veterinary Journal (1998), 155(2), 201-203

Detailed reference viewed: 61 (3 ULg)
Full Text
Peer Reviewed
See detailThe Effect of Intravenous Administration of Web 2086 on Paf-Induced Platelet Aggregation in Healthy Friesian Calves
Bastos da Silva, Miriam; Gustin, Pascal ULg; Herion, Francine ULg et al

in Veterinary Research Communications (1997), 21(7), 521-531

The in vivo ability of the specific PAF-antagonist WEB 2086, a thienotriazolodiazepine, to inhibit platelet-activating factor (PAF) in cattle was investigated by in vitro determination of platelet ... [more ▼]

The in vivo ability of the specific PAF-antagonist WEB 2086, a thienotriazolodiazepine, to inhibit platelet-activating factor (PAF) in cattle was investigated by in vitro determination of platelet aggregation curves. WEB 2086 was infused intravenously into a group of 5 healthy male Friesian calves in a dose of 3 mg/kg over 1 min. The resultant inhibition peaked between 30 min and 1 h after administration of WEB 2086. The inhibition was significantly reduced after 3 h and became non-significant after 6 h, but maximal pre-treatment aggregation had not been restored by 24 h after the injection of WEB 2086. These results confirm previous results obtained in vitro and suggest that WEB 2086 is a potent antagonist of PAF activity in calves. They also suggest that further clinical studies with WEB 2086 in cattle are desirable. [less ▲]

Detailed reference viewed: 46 (5 ULg)
Full Text
Peer Reviewed
See detailCombined Effect of Web 2086 (Paf Antagonist) and Ketoprofen (Nsaid) on Paf-Induced Ex Vivo Platelet Aggregation in Bovine
Bastos da Silva, Miriam; Herion, Francine ULg; Raskinet, Renée ULg et al

in Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine (1997), 44(2), 65-71

The effect of the specific PAF-antagonist WEB 2086, a thieno-triazolo-diazepine, and ketoprofen, a NSAID, was investigated on PAF-induced bovine platelet aggregation measured ex vivo in platelet-rich ... [more ▼]

The effect of the specific PAF-antagonist WEB 2086, a thieno-triazolo-diazepine, and ketoprofen, a NSAID, was investigated on PAF-induced bovine platelet aggregation measured ex vivo in platelet-rich plasma (PRP). WEB 2086 was infused intravenously over 1 min followed immediately by ketoprofen administration over 1 s (both drugs = 3 mg/kg), in a group of six healthy male Friesian calves. Depending on the PAF concentration, a reversible (10(-8)-10(-9) mol/l) and irreversible (10(-5)-10(-7) mol/l) platelet aggregation was observed. The reversible aggregation was completely blocked by pretreatment of the animal with WEB 2086 and ketoprofen. The inhibitory effects observed during the irreversible aggregation were 47.22%, 54.00% and 88.00% at 10(-5), 10(-6) and 10(-7) mol/l PAF, respectively. Moreover, the aggregation obtained in these condition became reversible. Maximal inhibitory effect of WEB 2086 and ketoprofen on PAF-induced platelet aggregation in calves was observed within 30 min after administration of both drugs. This inhibition persisted even after 24 h and was significantly different from control with P < 0.05. The combined effect of both drugs exceeded the sum of the individual effects (synergism). It was concluded that WEB 2086 and ketoprofen very effectively blocked PAF-induced bovine platelet aggregation in platelet-rich plasma. The study also suggested a synergism between both substances. [less ▲]

Detailed reference viewed: 86 (0 ULg)
Full Text
Peer Reviewed
See detailInhibition of Paf-Induced Platelet Aggregation by Web 2086 'in-Vitro', an Antagonist to the Receptor for Platelet-Activating Factor, in Bovine
Bastos da Silva, Miriam; Herion, Francine ULg; Raskinet, Renée ULg et al

in Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine (1996), 43(7), 399-413

The sensitivity of bovine platelet aggregation in response to PAF stimulation and the ability of WEB 2086 (a thieno-triazolodiazepine) to inhibit response to PAF-induced platelet aggregation were ... [more ▼]

The sensitivity of bovine platelet aggregation in response to PAF stimulation and the ability of WEB 2086 (a thieno-triazolodiazepine) to inhibit response to PAF-induced platelet aggregation were investigated in the blood from five healthy male Belgian Blue calves. The recorded response to PAF showed a plateau which was dependent on the PAF concentration. Platelet aggregation induced by PAF consists of two mechanisms: reversible and irreversible aggregations which are accompanied by the release of platelet granule contents. Reversible aggregation occurred above (2 . 10(-9) mol/l) PAF, and irreversible aggregation occurred above (2 . 10(-7) mol/l) PAF. Addition of WEB 2086 to bovine platelets in vitro induced a rightward shift in the dose-response curve to PAF. WEB 2086 inhibited PAF-induced aggregation in a competitive reversible manner (pA2 = 7.61). The results of our study show that PAF induces platelet aggregation in platelet-rich plasma (PRP) and that addition of WEB 2086 to bovine platelets in vitro inhibits PAF-induced Platelet Aggregation. [less ▲]

Detailed reference viewed: 69 (3 ULg)